Double maintains 2 strategies that include SYRE - Spyre Therapeutics, Inc.
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that it has initiated dosing in a healthy volunteer, Phase 1 clinical trial of its investigational half-life extended anti-IL-23 monoclonal antibody, SPY003. This milestone marks our
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, dose optimization and rational therapeutic combinations to target improved efficacy and convenience in the treatment of IBD and other immune-mediated diseases, today announced that Spyre's independent Compensation Committee of the Board of Directors approved the grant of stock options to purchase 132,200 shares of common stock of Spyre to five n
SeekingAlpha
Spyre Therapeutics' innovative combination therapy approach targets multiple inflammatory pathways. Learn why SYRE stock is a Buy.
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced that management will participate in the following upcoming investor conferences:
Yahoo
Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the "Company" or "Spyre"), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and rational therapeutic combinations for the treatment of Inflammatory Bowel Disease ("IBD") and other immune-mediated diseases, today announced a poster presentation at the 20th Congress of the European Crohn's and Colitis Organisation (ECCO), held February 19-22, 2025, in Berlin, Germany, showing that combined inhibition of
Finnhub
NEW YORK, Jan. 28, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Spyre Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
BEAM | 46.99% | $1.85B | -37.74% | 0.00% |
IMNM | 46.81% | $583.44M | -68.94% | 0.00% |
APGE | 46.56% | $2.25B | -36.95% | 0.00% |
OVID | 46.55% | $24.17M | -88.85% | 0.00% |
ACLX | 46.01% | $3.69B | +6.38% | 0.00% |
CRSP | 45.99% | $2.93B | -47.07% | 0.00% |
IDYA | 45.42% | $1.43B | -61.21% | 0.00% |
BLFS | 44.66% | $1.12B | +37.30% | 0.00% |
KRYS | 43.59% | $5.21B | +1.76% | 0.00% |
RXRX | 42.47% | $2.13B | -40.76% | 0.00% |
NTLA | 41.81% | $755.67M | -70.78% | 0.00% |
RCKT | 41.68% | $671.77M | -75.23% | 0.00% |
VSH | 41.59% | $2.16B | -28.21% | 2.94% |
FATE | 41.41% | $88.24M | -89.02% | 0.00% |
KYMR | 40.23% | $1.71B | -29.01% | 0.00% |
SYNA | 40.22% | $2.50B | -32.72% | 0.00% |
RGNX | 39.94% | $353.11M | -65.19% | 0.00% |
ATXS | 39.83% | $311.52M | -54.38% | 0.00% |
XNCR | 39.73% | $691.94M | -54.37% | 0.00% |
RYTM | 39.50% | $3.29B | +27.07% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
CBOE | -19.93% | $23.50B | +25.53% | 1.05% |
CL | -12.65% | $75.88B | +6.19% | 2.07% |
BTCT | -11.67% | $20.15M | +14.57% | 0.00% |
PEP | -11.46% | $204.52B | -12.12% | 3.52% |
KDP | -10.51% | $47.68B | +13.32% | 2.55% |
VHC | -9.97% | $35.77M | +37.68% | 0.00% |
KO | -9.11% | $306.97B | +19.22% | 2.66% |
CME | -9.09% | $94.61B | +23.82% | 3.89% |
VZ | -9.08% | $188.34B | +4.44% | 5.84% |
T | -8.62% | $201.99B | +59.80% | 3.85% |
KMB | -8.51% | $47.39B | +13.36% | 3.37% |
ED | -8.23% | $38.69B | +21.90% | 2.95% |
HMST | -8.22% | $237.65M | -11.67% | 0.00% |
PULM | -8.01% | $22.13M | +234.81% | 0.00% |
CLX | -7.93% | $18.19B | +0.54% | 3.24% |
FATBB | -7.75% | $56.94M | -23.78% | 14.95% |
STG | -7.12% | $28.76M | -44.31% | 0.00% |
HRL | -6.68% | $16.84B | -11.83% | 3.62% |
SUN | -6.55% | $8.06B | -1.02% | 6.07% |
AEP | -6.25% | $57.54B | +27.77% | 3.31% |
Current Value
$14.471 Year Return
Current Value
$14.471 Year Return
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -35.64% | $416.76M | 1.43% |
VIXY | -28.05% | $195.31M | 0.85% |
TAIL | -26.90% | $87.65M | 0.59% |
UUP | -14.43% | $325.79M | 0.77% |
USDU | -14.10% | $206.96M | 0.5% |
UGA | -9.50% | $87.23M | 0.97% |
TPMN | -8.22% | $33.32M | 0.65% |
DBE | -8.15% | $55.52M | 0.77% |
TAXF | -8.09% | $517.32M | 0.29% |
BNO | -7.86% | $99.25M | 1% |
USO | -7.09% | $972.70M | 0.6% |
CARY | -5.96% | $347.36M | 0.8% |
CTA | -5.80% | $978.30M | 0.76% |
DBO | -5.60% | $202.41M | 0.77% |
JMST | -5.54% | $3.54B | 0.18% |
USL | -5.39% | $47.77M | 0.85% |
OILK | -5.36% | $67.85M | 0.69% |
DBA | -4.68% | $829.48M | 0.93% |
SHYD | -4.60% | $319.95M | 0.35% |
USCI | -4.54% | $240.82M | 1.07% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
CCOR | <0.01% | $64.12M | 1.18% |
PDBC | 0.03% | $4.89B | 0.59% |
STPZ | 0.08% | $427.83M | 0.2% |
FLTR | -0.12% | $2.41B | 0.14% |
MLN | 0.13% | $534.56M | 0.24% |
BILS | 0.15% | $3.67B | 0.1356% |
VGSH | -0.16% | $22.52B | 0.03% |
BAB | 0.23% | $977.85M | 0.28% |
DBC | -0.29% | $1.36B | 0.87% |
TYA | 0.33% | $158.79M | 0.15% |
SCHO | 0.37% | $10.65B | 0.03% |
HTAB | 0.40% | $450.03M | 0.39% |
UNG | -0.45% | $397.59M | 1.06% |
FLGV | 0.52% | $959.69M | 0.09% |
SMMU | 0.55% | $684.32M | 0.35% |
TDTT | 0.56% | $2.38B | 0.18% |
IBD | -0.60% | $382.70M | 0.44% |
XONE | -0.61% | $631.21M | 0.03% |
VTEB | 0.66% | $36.03B | 0.03% |
SCHR | 0.69% | $10.47B | 0.03% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 58.12% | $4.76B | 0.35% |
CPRJ | 56.44% | $48.38M | 0.69% |
GNOM | 54.23% | $47.13M | 0.5% |
ARKG | 54.06% | $936.86M | 0.75% |
IBB | 53.86% | $5.61B | 0.45% |
IWC | 49.31% | $797.08M | 0.6% |
PBE | 48.53% | $224.98M | 0.58% |
IWO | 48.42% | $10.72B | 0.24% |
PTH | 47.92% | $107.91M | 0.6% |
RSPA | 47.66% | $292.67M | 0% |
QQA | 47.42% | $187.77M | 0% |
VTWO | 47.02% | $10.92B | 0.07% |
IWM | 46.98% | $62.65B | 0.19% |
KOMP | 46.90% | $1.95B | 0.2% |
SCHA | 46.78% | $15.94B | 0.04% |
VBK | 46.47% | $17.32B | 0.07% |
ISCG | 46.09% | $655.02M | 0.06% |
KAPR | 46.03% | $144.85M | 0.79% |
ARKK | 45.80% | $5.03B | 0.75% |
NUSC | 45.72% | $1.10B | 0.31% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
XPOF | 0.02% | $275.36M | -45.12% | 0.00% |
KNOP | -0.03% | $260.66M | +43.40% | 1.46% |
TR | -0.04% | $2.24B | +3.83% | 1.15% |
PRPH | 0.18% | $11.65M | -94.11% | 0.00% |
BF.B | -0.26% | $16.31B | -33.43% | 2.66% |
FLO | 0.31% | $4.00B | -18.06% | 5.03% |
JKHY | -0.34% | $13.42B | +8.13% | 1.20% |
WM | 0.36% | $94.32B | +11.47% | 1.30% |
ROOT | 0.38% | $1.90B | +83.78% | 0.00% |
SCM | 0.40% | - | - | 11.70% |
POST | -0.40% | $6.54B | +11.31% | 0.00% |
BNED | 0.42% | $364.72M | -83.00% | 0.00% |
KVUE | 0.44% | $45.62B | +17.35% | 3.43% |
CNK | 0.45% | $3.03B | +32.57% | 0.33% |
UUU | -0.48% | $4.14M | +11.18% | 0.00% |
SITC | -0.49% | $675.30M | +17.17% | 1.08% |
DUK | -0.52% | $93.55B | +25.45% | 3.37% |
CQP | 0.57% | $32.91B | +35.41% | 5.06% |
TRVG | 0.61% | $104.93M | +63.70% | 0.00% |
MPAA | 0.63% | $185.26M | +19.14% | 0.00% |